Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;101(3):115504.
doi: 10.1016/j.diagmicrobio.2021.115504. Epub 2021 Jul 24.

Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis

Ashley Lorenz  1 , Mohammad Mahdee E Sobhanie  2 , Libby Orzel  1 , Kelci Coe  2 , Lynn Wardlow  3
Affiliations

Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis

Ashley Lorenz et al. Diagn Microbiol Infect Dis. 2021 Nov.

Abstract

The objective of this single-center, retrospective cohort study was to identify whether combination therapy is associated with a lower rate of adverse outcomes for the treatment of Gram negative non-HACEK IE. The primary endpoint was a composite of 60-day all-cause mortality, readmission, or recurrence of bacteremia. Of the 60 patients included, 56.7% met the primary composite outcome, with 20% overall mortality at 60 days. There was no difference in the primary composite outcome of 60-day readmission, infection recurrence or mortality between groups, with 62% of patients in the monotherapy group and 50% of patients in the combination therapy group experiencing the composite outcome (P = 0.36). Despite the high mortality and complicated nature of non-HACEK Gram negative IE, this study showed no difference in 60-day bacteremia recurrence, readmission or mortality among patients treated with combination therapy or monotherapy, suggesting that monotherapy may lead to similar clinical outcomes.

Keywords: Combination therapy; Gram negative bacteria; Infective endocarditis.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest: None

Figures

Figure 1:
Figure 1:. Study Population
ICD, International Classification of Diseases; IE, infective endocarditis; CLABSI, central line-associated blood stream infection
See this image and copyright information in PMC

References

    1. Ertugrul Mercan M, Arslan F, Ozyavuz Alp S, et al. Non-HACEK Gram-negative bacillus endocarditis. Medecine et maladies infectieuses. 2019. 10.1016/j.medmal.2019.03.013 - DOI - PubMed
    1. Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative bacillus endocarditis. Annals of internal medicine. 2007;147(12):829–835. 10.7326/0003-4819-147-12-200712180-00002 - DOI - PubMed
    1. Reyes MP, Reyes KC. Gram-negative endocarditis. Current infectious disease reports. 2008;10(4):267–274. 10.1007/s11908-008-0044-5 - DOI - PubMed
    1. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435–1486.10.1161/CIR.0000000000000296 - DOI - PubMed
    1. Falcone M, Tiseo G, Durante-Mangoni E, et al. Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. Antimicrobial agents and chemotherapy. 2018;62(4). 10.1128/AAC.02208-17 - DOI - PMC - PubMed

MeSH terms

Substances